Table 2 SLEDAI-2K, laboratorial characteristics and treatment of juvenile systemic lupus erythematosus (JSLE) patients before (D0) and after vaccination (D30)
D0 (n = 24) | D30 (n = 24) | p | |
|---|---|---|---|
Disease parameters | |||
SLEDAI-2K score | 2 (0–17) | 2 (0–17) | 0.765 |
Positive Anti-dsDNA | 9 (38) | 9 (38) | 0.480 |
Hypocomplementemia | 4 (17) | 3 (13) | 1.000 |
Leukocytes, × 103 | 5.09 (1.39–13.7) | 4.9 (1.76–11.11) | 0.989 |
Leukopenia % < 4000 | 6 (25) | 7 (29.1) | 1.000 |
Lymphocytes, × 103 | 1.52 (0.17–3.15) | 1.5 (0.65–2.78) | 0.648 |
Lymphopenia % < 1500 | 11 (45.8) | 12 (50) | 1.000 |
Treatment | |||
Hydroxychloroquine | 24 (100) | 24 (100) | 1.000 |
Prednisone | 15 (62.5) | 15 (62.5) | 1.000 |
Current dose, mg/day | 15 (2.5–30) | 15 (2.5–30) | 1.000 |
Azathioprine | 5 (21) | 6 (25) | 1.000 |
Mycophenolate mofetil | 12 (50) | 12 (50) | 1.000 |
IVCYC | 0 (0) | 0 (0) | 1.000 |
Methotrexate | 4 (17) | 4 (17) | 1.000 |
Current dose, mg/week | 17.5 (7.5–25) | 17.5 (7.5–25) | 1.000 |
Rituximab | 0 (0) | 0 (0) | 1.000 |